Treatment principles for candida and cryptococcus

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 6, 2015, Pages 1-12

  Whitney, Laura C ^a   Bicanic, Tihana ^b  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FUNGAL POLYSACCHARIDE; VORICONAZOLE; ANTIRETROVIRUS AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; BONE INFECTION; CANDIDA; CANDIDA ENDOCARDITIS; CANDIDEMIA; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTION; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; DRUG EFFICACY; EYE INFECTION; FILOBASIDIELLA; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS COMPLICATION; INFLAMMATION; INTRACRANIAL PRESSURE; NEPHROTOXICITY; NONHUMAN; PATIENT MONITORING; PERSISTENT INFECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTHESIS INFECTION; PROSTHESIS MATERIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; RELAPSE; RISK ASSESSMENT; SCREENING; SPECIES IDENTIFICATION; SURGICAL DRAINAGE; UROGENITAL TRACT INFECTION; BONE DISEASES, INFECTIOUS; CENTRAL NERVOUS SYSTEM INFECTIONS; CHRONIC DISEASE; COINFECTION; ENDOCARDITIS; EYE INFECTIONS, FUNGAL; IMMUNOCOMPROMIZED PATIENT; INTRACRANIAL HYPERTENSION; MICROBIAL SENSITIVITY TEST; RECURRENT DISEASE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

CANDIDA;

ANTI-RETROVIRAL AGENTS; ANTIFUNGAL AGENTS; BONE DISEASES, INFECTIOUS; CANDIDIASIS; CENTRAL NERVOUS SYSTEM INFECTIONS; CHRONIC DISEASE; COINFECTION; CRYPTOCOCCOSIS; ENDOCARDITIS; EYE INFECTIONS, FUNGAL; HUMANS; IMMUNOCOMPROMISED HOST; INTRACRANIAL HYPERTENSION; MICROBIAL SENSITIVITY TESTS; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84926315610     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a024158     Document Type: Article

References (93)

1. Alexander B, Johnson M, Pfeiffer C, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56: 1724-1732.
2. Baddley JW, Benjamin DK Jr, Patel M, Miró J, Athan E, Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, et al. 2008. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 27: 519-529.
3. Bassett M, Mikulska M, Viscoli C. 2010. Bench-to-bedside review: Therapeutic management of invasive candidiasis in the intensive care unit. Crit Care 14: 244-255.
4. Benjamin DJ, Poole C, SteinbachW, Rowen J, Walsh T. 2003. Neonatal candidemia and end-organ damage: A critical appraisal of the literature using meta-analytic techniques. Pediatrics 112: 634-640.
5. Bicanic T, Harrison T, Niepieklo A, Dyakopu N, Meintjes G. 2006. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: The role of fluconazole resistance and immune reconstitution. Clin Infect Dis 43: 1069-1070.
6. Bicanic T, Wood R, Meintjes G, Rebe K, Brouwer AE, Loyse A, Bekker LG, Jaffar S, Harrison T. 2008. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial. Clin Infect Dis 47: 123-130.
7. Bicanic T, Meintjes G, Rebe K, Williams A, Loyse A, Wood R, HAYES M, Jaffar S, Harrison TS. 2009a. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: A prospective study. J Acquir Immune Defic Syndr 51: 130-134.
8. Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, Teparrakkul P, Loyse A, White NJ, Wood R. 2009b. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 23: 701-706.
9. Bicanic T, Muzoora C, Brouwer AE, Meintjes G, Longley N, Taseera K, Rebe K, Loyse A, Jarvis J, Bekker L. 2009c. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: Analysis of a combined cohort of 262 patients. Clin Infect Dis 49: 702-709.
10. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Musubire A, Lee SJ, Kambugu A, Janoff EN, Bohjanen PR. 2010. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: A prospective cohort study. PLoS Med 7: e1000384.
11. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, NabetaHW, Schutz C, WilliamsDA, et al. 2014. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. New Engl J Med 370: 2487-2498.
12. Branch RA. 1988. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation. Arch Intern Med 148: 2389.
13. Breit S, Hariprasad S, MielerW, Shah G, Mills M, Grand M. 2005. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 139: 135-140.
14. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, Harrison TS. 2004. Combination antifungal therapies for HIV-associated cryptococcal meningitis: A randomised trial. Lancet 363: 1764-1767.
15. Chandrasekar P, Sobel J. 2006. Micafungin: A new echinocandin. Clin Infect Dis 42: 1171-1178.
16. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ. 2013. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 368: 1291-1302.
17. Deresinski S, Stevens D. 2003. Caspofungin. Clin Infect Dis 36: 1445-1457.
18. De Vedia L, Arechavala A, Calderón M, Maiolo E, Rodríguez A, Lista N, Di Virgilio E, Cisneros J, Prieto R. 2013. Relevance of intracranial hypertension control in the management of Cryptococcus neoformans meningitis related to AIDS. Infection 41: 1073-01077.
19. Donahue SP, Greven CM, Zuravleff JJ, Eller AW, Nguyen MH, Peacock JE Jr, Wagener MW, Yu VL. 1994. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 101: 1302-1309.
20. Donhuijsen K, Pfaffenbach B, Samandari S, Leder L. 1991. Autopsy results of deep mycoses in hematologic neoplasms 1053 patients. Mycoses 34: 25-27.
21. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W. 2001. Fungal endocarditis: Evidence in the world literature 1965-1995. Clin Infect Dis 32: 50-62.
22. Engel C, Brunkhorst F, Bone H, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, JaschinskiU, John S, et al. 2007. Epidemiology of sepsis in Germany: Results from a national prospective multicenter study. Intensive Care Med 33: 606-618.
23. Essman TF, Flynn HW Jr, Smiddy WE, Brod RD, Murray TG, Davis JL, Rubsamen PE. 1997. Treatment outcomes in a 10-year study of endogenous fungal endophthalmitis. Ophthalmic Surg Lasers 28: 185-194.
24. Farmaki E, Evdoridou J, Pouliou T, Bibashi E, Panagopoulou P, Filioti J, Benos A, Sofianou D, Kremenopoulos G, Roilides E. 2007. Fungal colonization in the neonatal intensive care unit: Risk factors drug susceptibility, and associationwith invasive fungal infections. AmJ Perinatol 24: 127-135.
25. Filioti J, Spiroglou K, Panteliadis CP, Roilides E. 2007. Invasive candidiasis in pediatric intensive care patients: Epidemiology, risk factors, management, and outcome. Intensive Care Med 33: 1272-1283.
26. French N, Gray K, Watera C, Nakiyingi J, Lugada E, Moore M, LallooD, Whitworth JA, Gilks CF. 2002. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16: 1031-1038.
27. Gallis HA, Drew RH, Pickard WW. 1990. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12: 308-329.
28. Garcia-Hermoso D, Janbon G, Dromer F. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 37: 3204-3209.
29. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study. Clin Infect Dis 43: 25-31.
30. Gauthier GM, Nork TM, Prince R, Andes D. 2005. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41: e27-e28.
31. Girmenia C, Cimino G, Di Cristofano F, Micozzi A, Gentile G, Martino P. 2005. Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: A prospective study in patients with hematological malignancies. Support Care Cancer 13: 987-992.
32. Glöckner A, Cornely OA. 2013. Practical considerations on current guidelines for the management of invasive candidiasis. Mycoses 56: 11-20.
33. Gould F, Denning D, Elliott T, Foweraker J, Perry JD, Prendergast BD, Sandoe JA, Spry MJ, Watkin RW, Working Party of the British Society for Antimicrobial Chemotherapy. 2012. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: A report of theWorking Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 67: 269-289.
34. Graybill JR, Sobel J, Saag M, Van Der Horst C, PowderlyW, Cloud G, Riser L, Hamill R, Dismukes WE. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. Clin Infect Dis 30: 47-54.
35. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172-1177.
36. Jarvis JN, Harrison TS. 2007. HIV-associated cryptococcal meningitis. AIDS 21: 2119-2129.
37. Jarvis JN, Meintjes G, Harrison TS. 2010. Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa. J Infect 60: 496.
38. + T-lymphocyte countstime to implement in South Africa? S Afr Med J 101: 232-234.
39. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR. 2011b. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine frompatientswith HIVassociated cryptococcal meningitis. Clin Infect Dis 53: 1019-1023.
40. Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C, Bekker L, Wood R, Harrison TS. 2012. Adjunctive interferon-immunotherapy for the treatment of HIV-associated cryptococcal meningitis: A randomized controlled trial. AIDS 26: 1105-1113.
41. Jarvis JN, Harrison TS, Lawn SD, Meintjes G, Wood R, Cleary S. 2013a. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS ONE 8: e69288.
42. Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, Harrison TS, Koup RA. 2013b. The phenotype of the Cryptococcus-specific CD4 memory T-cell response is associated with disease severity and outcome in HIVassociated cryptococcal meningitis. J Infect Dis 207: 1817-1828.
43. Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, Longley N, et al. 2014. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. Clin Infect Dis 58: 736-745.
44. Johnson LB, Kauffman CA. 2003. Voriconazole: A new triazole antifungal agent. Clin Infect Dis 36: 630-637.
45. Joly V, Aubry P, Ndayiragide A, Carrière I, Kawa E, Mlika-Cabanne N, Aboulker J, Coulaud J, Larouze B, Yeni P. 1996. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 23: 556-562.
46. Khan FA, Slain D, Khakoo RA. 2007. Candida endophthalmitis: Focus on current and future antifungal treatment options. Pharmacotherapy 27: 1711-1721.
47. Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. 2012. Septic shock attributed to Candida infection: Importance of empiric therapy and source control. Clin Infect Dis 54: 1739-1739.
48. Kullberg BJ, Verweij PE, Akova M, Arendrup MC, Bille J, Calandra T, Cuenca-Estrella M, Herbrecht R, Jacobs F, Kalin M, et al. 2011. European expert opinion on the management of invasive candidiasis in adults. Clin Microbiol Infect 17: 1-12.
49. Labelle AJ, Micek ST, Roubinian N, Kollef MH. 2008. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 36: 2967-2972.
50. Leenders AC, Daenen S, Jansen RL, HopWC, Lowenberg B, Wijermans PW, Cornelissen J, Herbrecht R, Lelie HVD, Hoogsteden HC. 1998. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 103: 205-212.
51. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, Downing R, Coutinho A, Mermin J. 2007. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12: 929-935.
52. Loyse A, Wilson D, Meintjes G, Jarvis JN, Bicanic T, Bishop L, Rebe K, Williams A, Jaffar S, Bekker L, et al. 2012. Comparison of the early fungicidal activity of highdose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 54: 121-128.
53. Lutsar I, Roffey S, Troke P. 2003. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 37: 728-732.
54. Martínez-Vázquez C, Fernández-Ulloa J, Bordón J, Sopeña B, de la Fuente J, Ocampo A, Rubianes M. 1998. Candida albicans endophthalmitis in brown heroin addicts: Response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 27: 1130-1133.
55. Masood A, Sallah S. 2005. Chronic disseminated candidiasis in patients with acute leukemia: Emphasis on diagnostic definition and treatment. Leuk Res 29: 493-501.
56. Mayer J, Doubek M, Doubek J, Horký D, Scheer P, Štěpánek M. 2002. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study. J Infect Dis 186: 379-388.
57. Meister H, Heymer B, Schäfer H, Haferkamp O. 1977. Role of Candida albicans in granulomatous tissue reactions: I. In vitro degradation of C. albicans and immunospecificity of split products. J Infect Dis 135: 224-234.
58. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR. 2010. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4 cell count ≤ 100 cells/μLwho start HIV therapy in resource-limited settings. Clin Infect Dis 51: 448-455.
59. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K, Richards MJ, Gottlieb T. 1995. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 20: 611-616.
60. Morrell M, Fraser VJ, Kollef MH. 2005. Delaying the empiric treatment of candida bloodstream infection until positive blood cultures are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 49: 3640-3645.
61. Muzoora CK, Kabanda T, Ortu G, Ssentamu J, Hearn P, Mwesigye J, Longley N, Jarvis JN, Jaffar S, Harrison TS. 2012. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infect 64: 76-81.
62. Mylonakis E, Calderwood SB. 2001. Infective endocarditis in adults. N Engl J Med 345: 1318-1330.
63. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, et al. 2010. Combination flucytosine and highdose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: A randomized trial in Malawi. Clin Infect Dis 50: 338-344.
64. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, et al. 2009a. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 48: 503-535.
65. Pappas PG, Chetchotisakd P, Larsen RA, Manosuthi W, Morris MI, Anekthananon T, Sungkanuparph S, Supparatpinyo K, Nolen TL, Zimmer LO. 2009b. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 48: 1775-1783.
66. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50: 291-322.
67. Pfaller M, Diekema D. 2012. The epidemiology of invasive candidiasis. ASM, Washington, DC.
68. Pierrotti LC, Baddour LM. 2002. Fungal endocarditis, 1995-2000. Chest 122: 302-310.
69. PowderlyWG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, Mcauliffe VJ, Follansbee SE. 1992. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 326: 793-798.
70. Raad I, Hanna H, Boktour M, Girgawy E, Danawi H, Mardani M, KontoyiannisD, Darouiche R, Hachem R, Bodey GP. 2004. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis 38: 1119-1127.
71. Ramage G, Saville SP, Thomas DP, López-Ribot JL. 2005. Candida biofilms: An update. Eukaryot Cell 4: 633-638.
72. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. 1993. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine 72: 207-224.
73. Rodríguez-Adrián LJ, King RT, Tamayo-Derat LG, Miller JW, Garcia CA, Rex JH. 2003. Retinal lesions as clues to disseminated bacterial and candidal infections: Frequency, natural history, and etiology. Medicine (Baltimore) 82: 187-202.
74. Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glöckner A, HeinzW, Höhl R, Horré R, Karthaus M, Kujath P, et al. 2011. Diagnosis and therapy of Candida infections: Joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 54: 279-310.
75. Saha D, Goldman D, Shao X, Casadevall A, Husain S, Limaye A, Lyon M, Somani J, Pursell K, Pruett T. 2007. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients. Clin Vaccine Immunol 14: 1550-1554.
76. Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin RT, Dawson J, Blumberg HM, Patterson JE, Rinaldi M, Edwards JE, et al. 2000. Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr Infect Dis J 19: 319-324.
77. Salamon SA, Fuursted K, Egeblad H, Petersen E, Ott P. 2007. Candida albicans tricuspid and pulmonic valve endocarditis: Challenge of relapsing risk and role of combined medical treatment and surgery. Scand J Infect Dis 39: 641-644.
78. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM. 2005. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 40: e46-e48.
79. Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, Schuler U, Lutsar I, Toke P, Thiel E. 2005. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 106: 2641-2645.
80. Schwesinger G, Junghans D, Schröder G, Bernhardt H, Knoke M. 2005. Candidosis and aspergillosis as autopsy findings from 1994 to 2003. Mycoses 48: 176-180.
81. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, Mildvan D, Fan-Havard P, Eng RH, Patterson TF. 1996. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 22: 308-314.
82. Snydman DR, Singh N, Dromer F, Perfect JR, Lortholary O. 2008. Cryptococcosis in solid organ transplant recipients: Current state of the science. Clin Infect Dis 47: 1321-1327.
83. Steinbach WJ, Perfect JR, Cabell CH, Fowler VG, Corey GR, Li JS, Zaas AK, Benjamin DK Jr. 2005. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 51: 230-247.
84. Thorn JL, Gilchrist KB, Sobonya RE, Gaur NK, Lipke PN, Klotz SA. 2010. Postmortem candidaemia: Marker of disseminated disease. J Clin Pathol 63: 337-340.
85. Tleyjeh IM, Abdel-Latif A, Rahbi H, Scott CG, Bailey KR, Steckelberg JM, Wilson WR, Baddour LM. 2007. A systematic review of population-based studies of infective endocarditis. Chest 132: 1025-1035.
86. Van Der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL. 1997. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 337: 15-21.
87. Vazquez JA, Sobel JD. 2006. Anidulafungin: A novel echinocandin. Clin Infect Dis 43: 215-222.
88. Vermes A, Guchelaar HJ, Dankert J. 2000. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 46: 171-179.
89. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, et al. 2009. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302: 2323-2329.
90. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. 1989. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med149: 2349-2353.
91. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. 2004. Nosocomial bloodstream infections in US hospitals: Analysis of 24, 179 cases from a prospective nationwide. Clin Infect Dis 39: 309-317.
92. Zaoutis TE, Greves HM, Lautenbach E, Bilker WB, Coffin SE. 2004. Risk factors for disseminated candidiasis in children with candidaemia. Paediatr Infect Dis 23: 635-641.
93. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: A propensity analysis. Clin Infect Dis 41: 1232-1239.